Simon Douglas
CEO
BIOFORTUNA
United Kingdom
Biography
Over 25 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was sold to Agilent Technologies Inc and is currently a director of the antibody-based therapeutics Company Fusion Antibodies.
Research Interest
Simon Douglas has research interest in life science and business management.
